DE69637381D1 - Prodrugs von pharmazeutika mit erhöhter bioverfügbarheit - Google Patents

Prodrugs von pharmazeutika mit erhöhter bioverfügbarheit

Info

Publication number
DE69637381D1
DE69637381D1 DE69637381T DE69637381T DE69637381D1 DE 69637381 D1 DE69637381 D1 DE 69637381D1 DE 69637381 T DE69637381 T DE 69637381T DE 69637381 T DE69637381 T DE 69637381T DE 69637381 D1 DE69637381 D1 DE 69637381D1
Authority
DE
Germany
Prior art keywords
progrugs
pharmaceuticals
increased bioavailability
lipid prodrugs
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69637381T
Other languages
English (en)
Other versions
DE69637381T2 (de
Inventor
Karl Y Hostetler
Ganesh D Kini
James R Beadle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE69637381D1 publication Critical patent/DE69637381D1/de
Publication of DE69637381T2 publication Critical patent/DE69637381T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/098—Esters of polyphosphoric acids or anhydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4062—Esters of acids containing the structure -C(=X)-P(=X)(XR)2 or NC-P(=X)(XR)2, (X = O, S, Se)
    • C07F9/4065—Esters of acids containing the structure -C(=X)-P(=X)(XR)2, (X = O, S, Se)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69637381T 1995-06-07 1996-06-07 Prodrugs von pharmazeutika mit erhöhter bioverfügbarheit Expired - Lifetime DE69637381T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US487081 1983-04-27
US08/487,081 US7517858B1 (en) 1995-06-07 1995-06-07 Prodrugs of pharmaceuticals with improved bioavailability
PCT/US1996/010054 WO1996039831A1 (en) 1995-06-07 1996-06-07 Prodrugs of pharmaceuticals with improved bioavailability

Publications (2)

Publication Number Publication Date
DE69637381D1 true DE69637381D1 (de) 2008-02-07
DE69637381T2 DE69637381T2 (de) 2008-12-11

Family

ID=23934330

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69637381T Expired - Lifetime DE69637381T2 (de) 1995-06-07 1996-06-07 Prodrugs von pharmazeutika mit erhöhter bioverfügbarheit

Country Status (9)

Country Link
US (1) US7517858B1 (de)
EP (1) EP0837630B1 (de)
JP (1) JP4301571B2 (de)
AT (1) ATE382051T1 (de)
AU (1) AU711774B2 (de)
CA (1) CA2223989C (de)
DE (1) DE69637381T2 (de)
ES (1) ES2299178T3 (de)
WO (1) WO1996039831A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9603726D0 (sv) * 1996-10-11 1996-10-11 Astra Ab Novel compounds
US6410328B1 (en) * 1998-02-03 2002-06-25 Protiva Biotherapeutics Inc. Sensitizing cells to compounds using lipid-mediated gene and compound delivery
EP1053023B2 (de) * 1998-02-03 2011-03-30 Protiva Biotherapeutics Inc. Systemische verabreichung von serum-stabilen plasmid-lipid partikeln zur krebstherapie
IL131887A0 (en) * 1999-09-14 2001-03-19 Dpharm Ltd Phospholipid prodrugs of anti-proliferative drugs
CA2395430A1 (en) * 1999-12-29 2001-07-05 The Regents Of The University Of California Treatment of drug-resistant human immunodeficiency virus infection
EP1460082A1 (de) * 2003-03-19 2004-09-22 Heidelberg Pharma Holding GmbH Phospholipidester von clofarabin-derivate
DE602005012155D1 (de) * 2004-11-03 2009-02-12 Liplasome Pharma As Arzneimittelabgabesysteme auf lipidbasis mit unnatürlichen phospholipase-a2-abbaubaren lipid-derivaten und ihre therapeutische verwendung
WO2006055525A2 (en) 2004-11-15 2006-05-26 Ceptyr, Inc. Protein tyrosine phosphatase inhibitors and methods of use thereof
ES2401285T3 (es) 2004-12-16 2013-04-18 The Regents Of The University Of California Fármacos con el pulmón como diana
WO2007107161A2 (en) * 2006-03-23 2007-09-27 Liplasome Pharma A/S Lipid based drug delivery systems comprising phospholipase a2 degradable lipids that perform an intramolecular cyclization reaction upon hydrolysis
US7749983B2 (en) * 2006-05-03 2010-07-06 Chimerix, Inc. Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates
JP5620272B2 (ja) * 2007-11-09 2014-11-05 プロノヴァ・バイオファーマ・ノルゲ・アーエスＰｒｏｎｏｖａ ＢｉｏＰｈａｒｍａ ＮｏｒｇｅＡＳ 化粧品において，食品サプリメントとして，または医薬品として用いるための脂質化合物
EP2070938A1 (de) * 2007-12-13 2009-06-17 Heidelberg Pharma AG Clofarabin-Dietherphospholipid-Derivate
CN102137676A (zh) * 2007-12-27 2011-07-27 伊皮芬尼生物科学公司 抗病毒化合物
WO2009090614A2 (en) * 2008-01-16 2009-07-23 Anwar Rayan Derivatives of taxol and closely related compounds
EP2147910A1 (de) * 2008-07-15 2010-01-27 Pronova BioPharma Norge AS Neue Lipid-Verbindungen
JP5843755B2 (ja) 2009-05-08 2016-01-13 プロノヴァ・バイオファーマ・ノルゲ・アーエスＰｒｏｎｏｖａ ＢｉｏＰｈａｒｍａ Ｎｏｒｇｅ ＡＳ 心血管性、代謝性および炎症性疾患領域に関する疾患の処置のための多価不飽和脂肪酸
US8884027B2 (en) 2010-10-22 2014-11-11 University Of Rochester Melampomagnolide B derivatives as antileukemic and cytotoxic agents
KR20200034814A (ko) 2010-11-05 2020-03-31 바스프 에이에스 지질 화합물을 이용한 치료방법
JP6537980B2 (ja) 2013-02-28 2019-07-03 プロノヴァ・バイオファーマ・ノルゲ・アーエスＰｒｏｎｏｖａ ＢｉｏＰｈａｒｍａ Ｎｏｒｇｅ ＡＳ 脂質化合物、トリグリセリドおよび界面活性剤を含む組成物、ならびにその使用方法
KR20150130355A (ko) 2013-03-15 2015-11-23 더 리전트 오브 더 유니버시티 오브 캘리포니아 비환식 뉴클레오사이드 포스포네이트 디에스테르
RU2665135C2 (ru) 2014-03-14 2018-08-28 Олтек, Инк. Композиции селеноорганических соединений и способы их применения
CN111808136B (zh) 2014-09-15 2024-06-11 加利福尼亚大学董事会 核苷酸类似物
US9771385B2 (en) 2014-11-26 2017-09-26 Vascular Biogenics Ltd. Oxidized lipids
JP6717825B2 (ja) 2014-11-26 2020-07-08 バスキュラー バイオジェニックス リミテッド 酸化脂質、および線維症の処置または予防方法
KR20220025914A (ko) 2015-03-06 2022-03-03 아테아 파마슈티컬즈, 인크. HCV 치료를 위한 β-D-2'-데옥시-2'-α-플루오로-2'-β-C-치환된-2-변형된-N6-치환된 퓨린 뉴클레오티드
CA2983377C (en) 2015-04-28 2023-08-29 Pronova Biopharma Norge As Use of structurally enhanced fatty acids containing sulphur for preventing and/or treating non-alcoholic steatohepatitis
WO2017048252A1 (en) 2015-09-15 2017-03-23 Alltech, Inc. Compositions of selenoorganic compounds and methods of use thereof
WO2017048956A1 (en) 2015-09-15 2017-03-23 The Regents Of The University Of California Nucleotide analogs
US10711029B2 (en) 2016-07-14 2020-07-14 Atea Pharmaceuticals, Inc. Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
KR20220146668A (ko) 2016-09-07 2022-11-01 아테아 파마슈티컬즈, 인크. Rna 바이러스 치료를 위한 2'-치환된-n6-치환된 퓨린 뉴클레오티드
CN111712240A (zh) 2017-12-06 2020-09-25 巴斯夫股份公司 用于治疗非酒精性脂肪性肝炎的脂肪酸衍生物
JP2022546310A (ja) 2019-08-22 2022-11-04 エモリー ユニバーシティー ヌクレオシドプロドラッグ及びそれに関する使用
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
WO2021173713A1 (en) 2020-02-27 2021-09-02 Atea Pharmaceuticals, Inc. Highly active compounds against covid-19
CA3188373A1 (en) 2020-08-24 2022-03-03 Scott E. Lazerwith Phospholipid compounds and uses thereof
TW202344257A (zh) 2020-10-16 2023-11-16 美商基利科學股份有限公司 磷脂化合物及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7607496L (sv) 1976-07-01 1978-01-02 Astra Laekemedel Ab Sett for bekempning av virusinfektioner
CA1140049A (en) 1977-12-22 1983-01-25 Dke J.E. Helgstran Pharmaceutical preparations from derivatives of hydroxycarbonylphosphonic acid
DE3374837D1 (en) * 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
JPS61152694A (ja) * 1984-12-27 1986-07-11 Toyama Chem Co Ltd 新規な５−フルオロ−２′−デオキシウリジン−５′−ホスフエ−ト誘導体およびその塩
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US5072032A (en) 1989-06-21 1991-12-10 Mckenna Charles E Preparation and use of thiophosphonates and thio-analogues of phosphonoformic acid
US5194654A (en) 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5411947A (en) * 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5463092A (en) * 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
WO1991016920A1 (en) 1990-05-07 1991-11-14 Vical, Inc. Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs
DE4111105A1 (de) * 1991-04-05 1992-10-08 Max Planck Gesellschaft Neue erucyl-, brassidyl- und nervonylderivate
DE4226279A1 (de) 1992-08-08 1994-02-10 Boehringer Mannheim Gmbh Liponucleotide von Seco-Nucleosiden, deren Herstellung sowie deren Verwendung als antivirale Arzneimittel
US5512671A (en) 1993-02-16 1996-04-30 Wake Forest University Ether lipid-nucleoside covalent conjugates
US5484911A (en) * 1993-04-01 1996-01-16 Health Research, Inc. Nucleoside 5'-diphosphate conjugates of ether lipids

Also Published As

Publication number Publication date
EP0837630A4 (de) 1998-11-25
DE69637381T2 (de) 2008-12-11
WO1996039831A1 (en) 1996-12-19
AU6171796A (en) 1996-12-30
US7517858B1 (en) 2009-04-14
JPH11512078A (ja) 1999-10-19
AU711774B2 (en) 1999-10-21
ES2299178T3 (es) 2008-05-16
JP4301571B2 (ja) 2009-07-22
CA2223989A1 (en) 1996-12-19
EP0837630B1 (de) 2007-12-26
CA2223989C (en) 2010-11-23
EP0837630A1 (de) 1998-04-29
ATE382051T1 (de) 2008-01-15

Similar Documents

Publication Publication Date Title
DE69637381D1 (de) Prodrugs von pharmazeutika mit erhöhter bioverfügbarheit
ATE264671T1 (de) Verfahren für die in-vivo-verabreichung von biologischen substanzen und hierfür verwendbare zusammensetzungen
DE69604653D1 (de) Taxol derivate, deren herstellung und diese enthaltende pharmazeutischen zusammenstellungen
ES2186769T3 (es) Complejos estables que comprenden lipidos para la administracion de farmacos y procedimientos para su produccion.
ES2145774T3 (es) Derivados de adenosina que tienen actividad agonista en a2.
FR2741066B1 (fr) Nouveaux agents de transfection et leurs applications pharmaceutiques
IS2537B (is) Lyfjablanda til inngjafar um húð
DE69805001D1 (de) Osmotische darreichungsform mit zwei mantelschichten
NO933854L (no) Promedikamenter, deres fremstilling og anvendelse som legemiddel
UY26372A1 (es) "imidazo-3-il-aminas bicíclicas procedimiento para su preparación y medicamentos que las contienen "
DE69630145D1 (de) Taxal derivate, deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
MX9203602A (es) Administracion iontoforetica mejorada de farmacos.
FR2764889B1 (fr) Nouveaux derives du 2-(iminomethyl)amino-phenyle, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
AR002982A1 (es) Benzonitrilos y benzofluoruros, un procedimiento para prepararlos, su empleo para preparar médicamentos, un médicamento hecho a base de estos compuestos, las preparaciónes farmacéuticas que los contienen y un procedimiento para obtener estas preparaciónes farmacéuticas.
ES2136725T3 (es) Utilizacion de 2-amino-6-n-propil-amino-4,5,6,7-tetrahidrobenzotiazol (pramipexol) como medicamento con efecto antidepresivo.
MX9102701A (es) Derivados de 2-acilamido de 3,4-dihidro-3-oxo-quinoxalina que tienen actividad farmaceutica.
MX9601994A (es) Profarmacos de derivados de paclitaxel.
ATE193533T1 (de) Taxal derivate, deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
DE69610085D1 (de) Taxol derivate,deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
IT8323058A0 (it) Derivati di 2,5-piperazindione biologicamente attivi, processi per la loro preparazione e composizioni farmaceutiche che licontengono.
FR2712289B1 (fr) Nouveaux dérivés de taxicine, leur préparation et les compositions pharmaceutiques qui les contiennent.
FR2691459B1 (fr) Nouveaux derives de la phenothiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
DE69626544T2 (de) Arzneistoffe
MA22880A1 (fr) Procede de preparation de produits pharmaceutiques .
ATE243683T1 (de) Polyhydroxybutylpyrazinen, deren herstellung und diese enthaltende arzneimitteln

Legal Events

Date Code Title Description
8364 No opposition during term of opposition